Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

Blue Jet Healthcare Investor Presentation: Key Takeaways

Blue Jet Healthcare reported Q1 FY27 Revenue of ₹2,931mn, up 25% QoQ but down 17.4% YoY. Strategy focuses on expanding R&D and CDMO adjacencies.

Highlights
Revenue growth25% QoQ growth driven by PI & API category.
MarginsEBITDA margin improved to 33.5% due to operating leverage.
Order book70% of total sales backed by contracted volumes.
Demand visibilityPI & API segments showing good traction this quarter.

Growth

EBITDA grew 37.6% QoQ to ₹981mn with a 33.5% margin. PAT increased 21.6% QoQ to ₹783mn.

Outlook

R&D center in Hyderabad operational by Sept'26. Raised ₹8,000mn via QIP for expansion and Vizag project.

Risks

YoY revenue decline driven by lower sales in Pharma Intermediates (₹1,210mn vs ₹2,120mn).

Last quarter's promises, checked

Delivered

  • Guided 3-4 new Contrast Media launches → delivered 19 additional intermediates (= BEAT)
  • Guided Vizag groundbreaking → delivered project activities commenced (= BEAT)
  • Guided PI segment normalization → delivered 5,046% QoQ surge in PI & API (= BEAT)

Partly delivered

  • Guided ₹400mn capex for FY27 → delivered ₹8,000mn QIP for accelerated expansion (= PARTIAL)

Missed

  • Guided flat FY26 revenue → delivered 8% YoY decline in FY26 (= MISS)
Source

Investor Presentation filed with NSE, NSE: BLUEJET. Summary written with AI assistance from the document.

Read the document ↗

Blue Jet Healthcare Ltd: key numbers

Share price
₹570.65
Market cap
₹9,899 Cr
Revenue (annual)
₹947.3 Cr
Net profit (annual)
₹247.8 Cr
P/E (TTM)
42.1×Sector 50.4×
Promoter holding
73.15%-6.66% QoQ
FII holding
0.63%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Blue Jet Healthcare Ltd

All →
13:15 IST NSE
Annual General Meeting

Blue Jet Healthcare Annual General Meeting

Blue Jet Healthcare held its 58th AGM, approving audited financials, a Re 1.20 dividend, and director re-appointments. No material amendments were noted.